Aurobindo gets USFDA approvals for two products

Eptifibatide injection is used in the treatment of acute coronary syndrome and Levonorgestrel tablet is an oral contraceptive used for prevention of pregnancy

Aurobindo Pharma Limited announced that the company has received final approval from the US Food and Drug Administration(USFDA) to manufacture and market Eptifibatide injection and Levonorgestrel tablet.

Eptifibatide injection is used in the treatment of acute coronary syndrome. The approved product has an estimated market size of $137 million for the twelve months ending October 2015 according to the company. This product is expected to be launched in this month.

Levonorgestrel tablet is an oral contraceptive used for prevention of pregnancy. The approved product has an estimated market size of $64 million for the twelve months ending October 2015, according to a company statement.